WO2005063285A1 - The sesl vaccine - Google Patents

The sesl vaccine Download PDF

Info

Publication number
WO2005063285A1
WO2005063285A1 PCT/IB2004/001387 IB2004001387W WO2005063285A1 WO 2005063285 A1 WO2005063285 A1 WO 2005063285A1 IB 2004001387 W IB2004001387 W IB 2004001387W WO 2005063285 A1 WO2005063285 A1 WO 2005063285A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
code
vaccine
sesl
hiv
Prior art date
Application number
PCT/IB2004/001387
Other languages
French (fr)
Original Assignee
Lacasse, Sacha, Emile, Stephan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lacasse, Sacha, Emile, Stephan filed Critical Lacasse, Sacha, Emile, Stephan
Publication of WO2005063285A1 publication Critical patent/WO2005063285A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • Previous vaccination techniques involve disabling a virus and placing it within the human bloodstream to force the human body to develop antibodies. That method is flawed in that if the virus was not totally disabled it could result in infection of the human subject. Even if 0.01% of the vaccinated population became infected, 1% of the population was resistant to the vaccine, and 10% of the population was unvaccinated a pandemic would result in large-scale fatalities. When dealing with a disease such as HIV it becomes necessary to produce a new process to create safe vaccines.
  • the SESL vaccination technique functions by engineering a new virus that is non-lethal, and has several properties in common with the virus you are vaccinating against while having different, less harmful genetic code.
  • the new virus is non-lethal and can still provide a vaccine for a lethal virus.
  • HIV which have no known prior vaccine, can be vaccinated against.
  • Vaccines occasionally have side effects if the virus was not totally deactivated, but with SESL vaccines these side effects would be no worse than a cold or the flu.
  • Virus A is the virus being vaccinated against
  • Virus B is the virus being used to assist in the creation of the vaccine
  • Virus C is the new less harmful virus used for vaccination
  • code A 1. Identify sections of the genetic code vital for the survival of Virus A, this is known as code A
  • code B Identify lethal sections of Virus A to avoid transference of these sections this code is known as code B
  • the end result of this method is a Virus C that produces the symptoms of Virus B (i.e. a flu virus), but that can only be killed the way Virus A can be killed.
  • the result is immunity to Virus A.
  • the human immunodeficiency virus functions by attacking the human immune system, and poses a great threat to human life.
  • step 1 vital portions of the virus are identified as
  • Gag, Pol, and Env are identified as structural, vital, and nonlethal.
  • Genetic code from Step 4 is removed from cold virus, modified cold virus is held for future use while the genetic code removed from the virus is destroyed.
  • Gag, Pol, and Env are removed from the HIV genetic code, remaining HIV is destroyed.
  • Gag, Pol, and Env from HIV are inserted into the modified cold virus.
  • the result is a virus that has the biological effects of a cold, along with the cold's reproductive capabilities and methods.
  • This new virus can then be deactivated and used as a vaccine for HIV, or implanted in its active state into a subject as a vaccine (once the symptoms of the cold are gone the person has HIV immunity).
  • Testing for HIV immunity can be done by injecting the new virus into a subject to check for cold symptoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The SESL vaccine eliminates the risks of infection through vaccination, and provides viable vaccination solutions for diseases like human immunodeficiency virus (HIV), through engineering new non-harmful viruses with certain properties.

Description

The SESL Vaccine
Description
Background:
Previous vaccination techniques involve disabling a virus and placing it within the human bloodstream to force the human body to develop antibodies. That method is flawed in that if the virus was not totally disabled it could result in infection of the human subject. Even if 0.01% of the vaccinated population became infected, 1% of the population was resistant to the vaccine, and 10% of the population was unvaccinated a pandemic would result in large-scale fatalities. When dealing with a disease such as HIV it becomes necessary to produce a new process to create safe vaccines.
The SESL vaccination technique functions by engineering a new virus that is non-lethal, and has several properties in common with the virus you are vaccinating against while having different, less harmful genetic code.
Advantages of the SESL vaccination technique
The new virus is non-lethal and can still provide a vaccine for a lethal virus.
Minimal understanding of a new virus is necessary to create an effective vaccine so long as certain precautions are taken.
Diseases such as HIV, which have no known prior vaccine, can be vaccinated against.
Vaccines occasionally have side effects if the virus was not totally deactivated, but with SESL vaccines these side effects would be no worse than a cold or the flu. Method
Virus A is the virus being vaccinated against
Virus B is the virus being used to assist in the creation of the vaccine
Virus C is the new less harmful virus used for vaccination
1. Identify sections of the genetic code vital for the survival of Virus A, this is known as code A
2. Identify lethal sections of Virus A to avoid transference of these sections this code is known as code B
3. Isolate the genetic code found in 1 from the genetic code identified in 2 (code A less code B), this code is named code C
4. Identify the genetic code in Virus B that performs the same functions as code C this code is known as code D
5. Remove code D from Virus B, store modified Virus B for later use
6. Remove code C from Virus A for implantation into Virus B
7. Implant code C into Virus B, the result is Virus C
The end result of this method is a Virus C that produces the symptoms of Virus B (i.e. a flu virus), but that can only be killed the way Virus A can be killed. The result is immunity to Virus A.
Example
HIV virus.
The human immunodeficiency virus functions by attacking the human immune system, and poses a great threat to human life.
Using step 1 vital portions of the virus are identified as
Env gpl20 Surface
Env gp41 transmembrane
HLA Class II
HLA Class I
Gag pi 7 Matrix
Gag p24 Capsid
Pol Reverse Transcriptase
Pol Integrase
Gag p7 nucleocapsid
Pol Protease
Gag pό
HIV RNA
Using Step 2 vif and vpr are identified as lethal
Using Step 3
Gag, Pol, and Env are identified as structural, vital, and nonlethal.
Using Step 4
Corresponding structural sections of a cold virus are identified Using Step 5
Genetic code from Step 4 is removed from cold virus, modified cold virus is held for future use while the genetic code removed from the virus is destroyed.
Using Step 6
Gag, Pol, and Env, are removed from the HIV genetic code, remaining HIV is destroyed.
Using Step 7
Gag, Pol, and Env from HIV are inserted into the modified cold virus.
The result is a virus that has the biological effects of a cold, along with the cold's reproductive capabilities and methods. This new virus can then be deactivated and used as a vaccine for HIV, or implanted in its active state into a subject as a vaccine (once the symptoms of the cold are gone the person has HIV immunity). Testing for HIV immunity can be done by injecting the new virus into a subject to check for cold symptoms.

Claims

ClaimsI claim SESL vaccines do
1. Provide safe vaccines
2. Provide vaccines against lethal viruses with little risk
3. Provide alternatives to other vaccines
4. Decrease risks of accidental infection
5. Decrease risks of infection associated with vaccination
6. Decrease side effects of vaccination
7. Provide vaccines against viruses like HIV
PCT/IB2004/001387 2003-12-22 2004-04-23 The sesl vaccine WO2005063285A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,451,549 2003-12-22
CA 2451549 CA2451549A1 (en) 2003-12-22 2003-12-22 The sesl vaccine

Publications (1)

Publication Number Publication Date
WO2005063285A1 true WO2005063285A1 (en) 2005-07-14

Family

ID=34683006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001387 WO2005063285A1 (en) 2003-12-22 2004-04-23 The sesl vaccine

Country Status (2)

Country Link
CA (1) CA2451549A1 (en)
WO (1) WO2005063285A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DING JIANPING ET AL: "Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1", STRUCTURE (CAMBRIDGE), vol. 10, no. 7, July 2002 (2002-07-01), pages 999 - 1011, XP002291593, ISSN: 0969-2126 *
SMITH ALLEN D ET AL: "Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 1, January 1998 (1998-01-01), pages 651 - 659, XP002191484, ISSN: 0022-538X *

Also Published As

Publication number Publication date
CA2451549A1 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
Garçon et al. From discovery to licensure, the Adjuvant System story
Greene AIDS and the immune system
Letvin Strategies for an HIV vaccine
RU2401665C2 (en) Immunogenic composition and method of elaboration of vaccine based on psoralen-inactivated hiv
Miyake et al. Induction of HIV‐specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV‐capturing nanospheres in macaques
Schneider-Ohrum et al. Virus-like particles for antigen delivery at mucosal surfaces
US20120207782A1 (en) Hiv dna vaccine regulated by a caev-derived promoter
Matthews et al. AIDS vaccines
Kang et al. Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines
Wodarz et al. Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long–term control of the virus
WO1994017825A1 (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
Geretti Simian immunodeficiency virus as a model of human HIV disease
Sadat Larijani et al. A shot at dendritic cell-based vaccine strategy against HIV-1
US8765140B2 (en) DNA vaccine compositions with HIV/SIV gene modifications
WO2005063285A1 (en) The sesl vaccine
Stott et al. Strategies for AIDS vaccines
Race et al. A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine
Cunningham et al. 3.1 Structure and function of HIV
Oxford et al. Challenges and strategies for AIDS vaccine development
Hanke Prospect of a prophylactic vaccine for HIV
Nabel Mapping the future of HIV vaccines.
EP2740488A1 (en) Sequential and repeated application of four or more hiv vector gene vaccines
Arora et al. HIV-1 therapeutic vaccine: a ray of hope
Altes et al. Intra-host competition between nef–defective escape mutants and wild–type human immunodeficiency virus type 1
Cohen AIDS Vaccines: Is Older Better? Researchers once wrote off vaccines based on live, weakened virus as far too dangerous, but recent data are causing some to rethink the old-fashioned approach

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase